| Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways P Eroles, A Bosch, J Alejandro Pérez-Fidalgo, A Lluch Cancer Treatment Reviews, 2011 | 968 | 2011 |
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014 | 700 | 2014 |
| MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ... Cell metabolism 26 (4), 633-647. e7, 2017 | 553 | 2017 |
| Management of chemotherapy extravasation: ESMO–EONS clinical practice guidelines JAP Fidalgo, LG Fabregat, A Cervantes, A Margulies, C Vidall, F Roila Annals of oncology 23, vii167-vii173, 2012 | 336 | 2012 |
| AKT Inhibition in Solid Tumors With AKT1 Mutations DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ... Journal of Clinical Oncology 35 (20), 2251-2259, 2017 | 299 | 2017 |
| Current questions for the treatment of advanced gastric cancer A Cervantes, D Roda, N Tarazona, S Roselló, JA Pérez-Fidalgo Cancer treatment reviews 39 (1), 60-67, 2013 | 228 | 2013 |
| Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients I Chirivella, B Bermejo, A Insa, A Pérez-Fidalgo, A Magro, S Rosello, ... Breast cancer research and treatment 114, 479-484, 2009 | 222 | 2009 |
| A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors C Saura, D Roda, S Roselló, M Oliveira, T Macarulla, JA Pérez-Fidalgo, ... Cancer discovery 7 (1), 102-113, 2017 | 171 | 2017 |
| Phase 1 Pharmacokinetic/Pharmacodynamic Study of MLN8237-An Investigational, Oral, Selective Aurora A Kinase Inhibitor-In Patients With Advanced Solid Tumors A Cervantes, E Elez, D Roda, JA Ecsedy, T Macarulla, K Venkatakrishnan, ... Clinical Cancer Research, 2012 | 169 | 2012 |
| Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial S Pernas, M Martin, PA Kaufman, M Gil-Martin, PG Pardo, ... The Lancet Oncology 19 (6), 812-824, 2018 | 135 | 2018 |
| A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ... Clinical Cancer Research 24 (9), 2050-2059, 2018 | 128 | 2018 |
| Concordance of genomic alterations between primary and recurrent breast cancer F Meric-Bernstam, GM Frampton, J Ferrer-Lozano, R Yelensky, ... Molecular cancer therapeutics 13 (5), 1382-1389, 2014 | 123 | 2014 |
| European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer I Vergote, A González-Martín, I Ray-Coquard, P Harter, N Colombo, ... Annals of Oncology 33 (3), 276-287, 2022 | 107 | 2022 |
| A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB) IA Mayer, A Prat, D Egle, S Blau, JAP Fidalgo, M Gnant, PA Fasching, ... Clinical Cancer Research 25 (10), 2975-2987, 2019 | 94 | 2019 |
| Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study EM de Dueñas, AL Hernández, ÁG Zotano, RMP Carrión, ... Breast cancer research and treatment 143, 507-515, 2014 | 93 | 2014 |
| Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations M Lambertini, L Ameye, AS Hamy, A Zingarello, PD Poorvu, E Carrasco, ... Journal of Clinical Oncology 38 (26), 3012-3023, 2020 | 89 | 2020 |
| Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens JA Pérez-Fidalgo, S Roselló, E García-Garré, E Jordá, P Martín-Martorell, ... Breast cancer research and treatment 120, 245-251, 2010 | 83 | 2010 |
| BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with … NC Turner, E Alarcón, AC Armstrong, M Philco, YAL Chuken, MP Sablin, ... Annals of Oncology 30 (5), 774-780, 2019 | 81 | 2019 |
| Pulmonary fibrosis induced by cyclophosphamide A Segura, A Yuste, A Cercos, P López-Tendero, R Gironés, ... Annals of Pharmacotherapy 35 (7-8), 894-897, 2001 | 76 | 2001 |
| MicroRNA profile in very young women with breast cancer M Peña-Chilet, MT Martínez, JA Pérez-Fidalgo, L Peiró-Chova, SS Oltra, ... BMC cancer 14, 1-14, 2014 | 74 | 2014 |
